The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.
The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback